PG 2

Drug Profile

PG 2

Alternative Names: Injectable astragalus polysaccharide; PG2; PHN011; PHN012; PHN013; PHN014; PHN015; Polysaccharides of Astragalus membranaceus; XueBao

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmagenesis
  • Developer Pharmagenesis; PhytoHealth
  • Class Phytotherapies; Polysaccharides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Fatigue; Leucopenia
  • Phase II Stroke
  • No development reported Idiopathic thrombocytopenic purpura

Most Recent Events

  • 19 Oct 2017 PhytoHealth Corporation plans a phase II trial for Fatigue (Cancer related) in Taiwan (NCT03314805)
  • 21 Sep 2017 Discontinued - Phase-I/II for Leucopenia in Taiwan (IV)
  • 06 Sep 2017 PG 2 is still in phase II trials for Stroke in Taiwan (PhytoHealth Pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top